口服抗生素与达巴万星对MRSA的协同作用
本研究采用标准时间-杀菌法,在五对同源金黄色葡萄球菌(敏感亲本株和达巴万星选择耐药株)中评估达巴万星与五种口服抗生素的协同作用。结果显示头孢羟氨苄与达巴万星对所有受试菌株均协同,甲氧苄啶和莫西沙星对部分菌株协同,多西环素和克拉霉素协同作用有限。
要点
- 头孢羟氨苄与达巴万星对所有受试菌株均显示协同作用。
- 甲氧苄啶和莫西沙星对部分菌株协同,且不太可能拮抗。
- 克拉霉素和多西环素最不可能提供获益。
核心结论
- 头孢羟氨苄与达巴万星协同作用普遍,且与两者敏感性无关,可能是有前景的联合药物。
研究设计与样本
- 采用五对同源金黄色葡萄球菌菌株(敏感亲本株和达巴万星选择耐药株),通过标准时间-杀菌法评估协同作用。
主要发现
- 头孢羟氨苄与达巴万星对所有受试菌株均协同。
- 甲氧苄啶与达巴万星对6/8甲氧苄啶敏感菌株协同。
- 莫西沙星与达巴万星对6/10菌株协同。
- 多西环素与达巴万星对2株菌协同但对2株菌拮抗。
- 克拉霉素与达巴万星对2/6克拉霉素敏感菌株协同。
临床怎么用
- 对于可能受益于协同活性以增强杀菌效果的深部感染患者,可考虑在达巴万星基础上加用头孢羟氨苄。
- 甲氧苄啶/磺胺甲噁唑和莫西沙星可能改善活性且不太可能拮抗。
- 克拉霉素和多西环素似乎最不可能提供获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We have shown that dalbavancin exposure can select for mutants with reduced susceptibilities to vancomycin and daptomycin, and several clinical cases of such resistance have been documented. Synergistic antimicrobial combinations may reduce resistance selection and enhance the activity of dalbavancin for deep-seated infections. Since the key advantage of dalbavancin is its infrequent dosing, the objective of this study was to evaluate whether orally bioavailable antibiotics typically dosed ≤ twice daily were synergistic with dalbavancin. METHODS: Using five isogenic S. aureus strain pairs (susceptible parent strain and a dalbavancin-selected resistant strain), we assessed for synergy between dalbavancin and cefadroxil, trimethoprim, doxycycline, moxifloxacin, and clarithromycin by standard time-kill methods. RESULTS: Cefadroxil was synergistic with dalbavancin against every strain tested. When combined with dalbavancin, trimethoprim was synergistic against 6/8 trimethoprim-susceptible strains, moxifloxacin was synergistic against 6/10 strains, doxycycline was synergistic against 2 strains but antagonistic against 2 strains, and clarithromycin was synergistic against 2/6 clarithromycin-susceptible strains. All other interactions were indifferent. CONCLUSIONS: Cefadroxil is a first-generation cephalosporin, like cephalexin, but with a longer half-life that allows for a typical 12-h dosing interval. In our study, we found that synergy between cefadroxil and dalbavancin was common regardless of susceptibility to cefadroxil or dalbavancin, suggesting that this might be a promising companion agent to add to dalbavancin in patients with deep-seated infections that may benefit from synergistic activity to enhance bactericidal effects. Trimethoprim/sulfamethoxazole and moxifloxacin may improve activity and are unlikely to be antagonistic. Clarithromycin and doxycycline seem least likely to offer a benefit.
引用
- Ahrendt E, Foreman MCL, Werth BJ, et al. Synergy between orally bioavailable antibiotics and dalbavancin against MRSA. J Antimicrob Chemother. 2026. PMID: 42572117. doi:10.1093/jac/dkag264
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。